NO975813L - Innkapslede celler som produserer virale partikler - Google Patents

Innkapslede celler som produserer virale partikler

Info

Publication number
NO975813L
NO975813L NO975813A NO975813A NO975813L NO 975813 L NO975813 L NO 975813L NO 975813 A NO975813 A NO 975813A NO 975813 A NO975813 A NO 975813A NO 975813 L NO975813 L NO 975813L
Authority
NO
Norway
Prior art keywords
encapsulated cells
viral particles
produce viral
cells
genes
Prior art date
Application number
NO975813A
Other languages
English (en)
Other versions
NO321427B1 (no
NO975813D0 (no
Inventor
Robert Michael Saller
Walter H Guenzburg
Brian Salmons
Original Assignee
Bavarian Nordic Res Inst As
Gsf Forschungszentrum Umwelt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8097001&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO975813(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bavarian Nordic Res Inst As, Gsf Forschungszentrum Umwelt filed Critical Bavarian Nordic Res Inst As
Publication of NO975813D0 publication Critical patent/NO975813D0/no
Publication of NO975813L publication Critical patent/NO975813L/no
Publication of NO321427B1 publication Critical patent/NO321427B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
    • C12N11/02—Enzymes or microbial cells immobilised on or in an organic carrier
    • C12N11/04—Enzymes or microbial cells immobilised on or in an organic carrier entrapped within the carrier, e.g. gel or hollow fibres
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
NO19975813A 1995-06-27 1997-12-10 Innkapslede celler som produserer virale partikler NO321427B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK74095 1995-06-27
PCT/EP1996/002748 WO1997001357A1 (en) 1995-06-27 1996-06-24 Encapsulated cells producing viral particles

Publications (3)

Publication Number Publication Date
NO975813D0 NO975813D0 (no) 1997-12-10
NO975813L true NO975813L (no) 1998-02-23
NO321427B1 NO321427B1 (no) 2006-05-08

Family

ID=8097001

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19975813A NO321427B1 (no) 1995-06-27 1997-12-10 Innkapslede celler som produserer virale partikler

Country Status (21)

Country Link
US (1) US6776985B1 (no)
EP (1) EP0835137B1 (no)
JP (2) JP4119952B2 (no)
KR (1) KR100484883B1 (no)
CN (1) CN1187095C (no)
AT (1) ATE309000T1 (no)
AU (1) AU708273B2 (no)
CA (1) CA2222559A1 (no)
CZ (1) CZ286979B6 (no)
DE (1) DE69633180D1 (no)
DK (1) DK0835137T3 (no)
ES (1) ES2253754T3 (no)
IL (1) IL122119A (no)
NO (1) NO321427B1 (no)
NZ (1) NZ312671A (no)
PL (1) PL185338B1 (no)
PT (1) PT835137E (no)
RU (1) RU2187301C2 (no)
SI (1) SI0835137T1 (no)
UA (1) UA65525C2 (no)
WO (1) WO1997001357A1 (no)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2198479T3 (es) 1995-03-09 2004-02-01 Gsf-Forschungszentrum Fur Umwelt Und Gesundheit Gmbh Vectores que llevan genes terapeuticos codificantes de peptidos antimicrobianos para terapia genica.
ATE309000T1 (de) 1995-06-27 2005-11-15 Bavarian Nordic As Verkapselte zellen die virenpartikeln produzieren
AU713382B2 (en) 1996-03-27 1999-12-02 Bavarian Nordic A/S Cytochrome P450 transducing retroviral vectors
US6540995B1 (en) 1996-03-27 2003-04-01 Bavarian Nordic Research Institute Gmbh Encapsulated cells producing cytochrome P450
CN1266362A (zh) 1998-05-05 2000-09-13 皇家菲利浦电子有限公司 包括具有刷毛区和齿间刷毛区的毛刷件的牙刷
AU2005229434B2 (en) 2004-03-30 2010-09-30 Nsgene A/S Therapeutic use of a growth factor, NsG33
US20090022785A1 (en) * 2005-05-03 2009-01-22 Veterinarmedizinische Universitat Wien Permeable Capsules
PL2231209T3 (pl) * 2007-12-20 2019-08-30 Ethicon, Incorporated Enkapsulowana tkanka nerkowa
KR101250925B1 (ko) * 2011-10-28 2013-04-04 한화케미칼 주식회사 캡슐 세포용 구조체
GB201408233D0 (en) 2014-05-09 2014-06-25 Austrianova Singapore Pte Ltd Use of polyanionic composition
ES2939617T3 (es) * 2015-11-24 2023-04-25 Glaxosmithkline Ip Dev Ltd Líneas celulares estables para producción retroviral
FR3044017B1 (fr) * 2015-11-24 2019-05-03 Glaxosmithkline Intellectual Property Development Limited Procede de transfection transitoire pour la production retrovirale
CN109153978B (zh) * 2016-05-25 2022-12-06 隆萨休斯敦股份有限公司 使用聚二烯丙基二烷基铵盐分离腺相关病毒的方法
RU2688383C2 (ru) * 2017-07-10 2019-05-21 Федеральное государственное бюджетное образовательное учреждение высшего образования "Саратовский национальный исследовательский государственный университет имени Н.Г. Чернышевского" Способ синтеза белка в культуре бактериальных клеток
CA3220737A1 (en) * 2021-05-21 2022-11-24 Bionaut Labs Ltd. System and method for localized therapeutic treatment
CN115820683B (zh) * 2022-09-28 2024-04-05 西南大学 家蚕Cyp9a20基因及其应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4391909A (en) * 1979-03-28 1983-07-05 Damon Corporation Microcapsules containing viable tissue cells
DD160393A3 (de) * 1980-11-14 1983-07-27 Horst Dautzenberg Mikrokapseln und verfahren zu ihrer herstellung
US4686098A (en) * 1984-05-14 1987-08-11 Merck & Co., Inc. Encapsulated mouse cells transformed with avian retrovirus-bovine growth hormone DNA, and a method of administering BGH in vivo
US4680174A (en) * 1984-05-24 1987-07-14 Damon Biotech, Inc. Induction of immune response by immunization with encapsulated antigen-producing cells
EP0199362A3 (en) * 1985-04-26 1987-10-07 Massachusetts Institute Of Technology System and apparatus for delayed and pulsed release of biologically active substances
CA1310924C (en) * 1986-04-24 1992-12-01 Francis P. Mccormick Infective drug delivery system
WO1989011539A1 (en) 1988-05-17 1989-11-30 Sloan-Kettering Institute For Cancer Research Retroviral vector
US5328470A (en) * 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
DE4021050A1 (de) * 1990-06-29 1992-01-02 Akad Wissenschaften Ddr Verfahren zur herstellung von mikrokapseln
CA2051288C (en) * 1990-09-14 2002-02-05 Robert L. Martuza Viral targeted destruction of neoplastic cells
CA2098510A1 (en) * 1990-12-13 1992-06-14 Kenneth W. Culver Sustained and continuous production of high titers of recombinant viral vectors and transduced target cells for use in gene therapy
WO1994029437A1 (en) 1993-06-07 1994-12-22 University Of Medicine & Dentistry Of New Jersey Highly-efficient, self-inactivating, recombination-free, u3-free retroviral vectors
US5688773A (en) 1994-08-17 1997-11-18 The General Hospital Corporation Method of selectively destroying neoplastic cells
RU2199585C2 (ru) 1994-09-02 2003-02-27 ГСФ-Форшунгсцентрум фюр Умвельт унд Гезундхайт ГмбХ Ретровирусная векторная конструкция, подвергающаяся промоторной конверсии, способ введения гомологичных или гетерологичных нуклеотидных последовательностей в человеческие или животные клетки in vitro и/или in vivo, рекомбинантная ретровирусная частица, фармацевтическая композиция для генной терапии
ATE309000T1 (de) 1995-06-27 2005-11-15 Bavarian Nordic As Verkapselte zellen die virenpartikeln produzieren
ES2174103T3 (es) 1995-09-06 2002-11-01 Austrian Nordic Biotherapeutic Uso de las secuencias reguladoras de wap o mmtv para expresion dirigida de genes heterologos ligados en celulas mamarias humanas, con inclusion de celulas de carcinoma mamario humano.
AU713382B2 (en) 1996-03-27 1999-12-02 Bavarian Nordic A/S Cytochrome P450 transducing retroviral vectors

Also Published As

Publication number Publication date
JP2008101011A (ja) 2008-05-01
ES2253754T3 (es) 2006-06-01
IL122119A (en) 2004-06-01
AU708273B2 (en) 1999-07-29
CA2222559A1 (en) 1997-01-16
EP0835137A1 (en) 1998-04-15
JPH11508768A (ja) 1999-08-03
UA65525C2 (en) 2004-04-15
CN1189104A (zh) 1998-07-29
NZ312671A (en) 1999-10-28
EP0835137B1 (en) 2005-11-09
CZ419597A3 (cs) 1998-03-18
KR100484883B1 (ko) 2005-09-02
SI0835137T1 (sl) 2006-04-30
CN1187095C (zh) 2005-02-02
NO321427B1 (no) 2006-05-08
PL324289A1 (en) 1998-05-11
NO975813D0 (no) 1997-12-10
CZ286979B6 (en) 2000-08-16
JP4119952B2 (ja) 2008-07-16
PL185338B1 (pl) 2003-04-30
US6776985B1 (en) 2004-08-17
AU6415496A (en) 1997-01-30
ATE309000T1 (de) 2005-11-15
JP4848348B2 (ja) 2011-12-28
KR19990028491A (ko) 1999-04-15
IL122119A0 (en) 1998-04-05
DE69633180D1 (de) 2004-09-23
DK0835137T3 (da) 2006-03-06
PT835137E (pt) 2004-12-31
WO1997001357A1 (en) 1997-01-16
RU2187301C2 (ru) 2002-08-20
HK1010139A1 (en) 1999-06-17

Similar Documents

Publication Publication Date Title
NO975813L (no) Innkapslede celler som produserer virale partikler
WO1992005266A3 (en) Packaging cells
MY116535A (en) New stable pharmaceutical preparation for producing propellant gas-free aerosols
EP1394259A3 (en) Recombinant infectious non-segmented negative strand RNA virus
BG103091A (en) Shortened soluble receptors of type i & ii of the tumour necrotizing factor
DK0758248T3 (da) Formuleringer til faktor IX
ATE308550T1 (de) Verwendungen von sulfatierten fuko- oligosacchariden zum pflanzenschutz
HUT76511A (en) Benzoyl derivatives, preparation and use thereot
DK1100789T3 (da) Substituerede benzoylcyclohexandioner
ES2026206T3 (es) Procedimiento para mejorar la expresion de proteina de eucariota.
WO1996007749A3 (en) Methods and compositions for inhibiting production of replication competent virus
BG101038A (bg) Супресия на растежа на туморни клетки посредствомсиндекан- 1 ектоучастък
IL145122A0 (en) C16 unsaturated fp-selective prostaglandin analogs
DE69814109D1 (de) 1,3-dihydroxy-20,20-dialkyl-vitamin d3 analoga
DK0843731T3 (da) Adenovirusvektorer til genterapi
SE9604582D0 (sv) Novel compounds
CA2239282A1 (en) Fused isoindolones as inhibitors of protein kinase c
YU48200A (sh) Farmaceutski preparati
FI971377A7 (fi) Adenovirusperäisiä virusvektoreita, joissa on kaksi terapeuttista geen iä: itsemurha- ja immuunistimuloiva geeni
ATE321549T1 (de) Bromierte hexahydroxybiphenylderivate
IL158356A0 (en) Benzoheterocycles
CA2331440A1 (en) Amphotropic retrovirus packaging cell line, process for its production and use thereof
AU6722498A (en) Disubstituted biphenyloxazolines
DE50006244D1 (en) Neue substituierte 3-phenoxy- und 3-phenylalkyloxy-2-phenyl-propylamine
PL318351A1 (en) Benzoyl derivatives and their synthesis

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees